List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6746292/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2010, 363, 1693-1703.	27.0	4,141
2	Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 2011, 3, 75ra26.	12.4	2,938
3	Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i> . Journal of Clinical Oncology, 2009, 27, 4247-4253.	1.6	1,775
4	Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Science Translational Medicine, 2012, 4, 120ra17.	12.4	1,138
5	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	9.4	1,108
6	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 2016, 22, 4585-4593.	7.0	977
7	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. Cancer Discovery, 2016, 6, 1118-1133.	9.4	919
8	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity, 2016, 44, 343-354.	14.3	767
9	Unique Clinicopathologic Features Characterize <i>ALK</i> -Rearranged Lung Adenocarcinoma in the Western Population. Clinical Cancer Research, 2009, 15, 5216-5223.	7.0	645
10	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science, 2014, 346, 1480-1486.	12.6	635
11	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	1.1	589
12	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications, 2015, 6, 6377.	12.8	498
13	Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature, 2015, 518, 240-244.	27.8	486
14	Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 2015, 5, 713-722.	9.4	429
15	Branch-Duct Intraductal Papillary Mucinous Neoplasms: Observations in 145 Patients Who Underwent Resection. Gastroenterology, 2007, 133, 72-79.	1.3	422
16	A Novel, Highly Sensitive Antibody Allows for the Routine Detection of <i>ALK</i> -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry. Clinical Cancer Research, 2010, 16, 1561-1571.	7.0	419
17	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. Gastroenterology, 2015, 149, 1501-1510.	1.3	376
18	CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors. Cancer Cell, 2014, 26, 136-149.	16.8	375

#	Article	IF	CITATIONS
19	Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Annals of Surgery, 2017, 265, 185-191.	4.2	366
20	Acquired Resistance to Crizotinib from a Mutation in <i>CD74</i> – <i>ROS1</i> . New England Journal of Medicine, 2013, 368, 2395-2401.	27.0	345
21	Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. Cancer Discovery, 2018, 8, 1529-1539.	9.4	342
22	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
23	Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics. Clinical Gastroenterology and Hepatology, 2010, 8, 213-219.e4.	4.4	289
24	<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology, 2019, 37, 278-285.	1.6	286
25	Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut, 2011, 60, 509-516.	12.1	277
26	Branch Duct Intraductal Papillary Mucinous Neoplasms. Annals of Surgery, 2013, 258, 466-475.	4.2	254
27	Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut, 2011, 60, 1712-1720.	12.1	244
28	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	1.1	234
29	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer. Cancer Discovery, 2018, 8, 714-729.	9.4	228
30	Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract. Annals of Surgery, 2016, 263, 162-177.	4.2	223
31	SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. Modern Pathology, 2020, 33, 2092-2103.	5.5	211
32	PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Modern Pathology, 2016, 29, 1104-1112.	5.5	210
33	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	1.1	203
34	FGFR1 Amplification in Squamous Cell Carcinoma of The Lung. Journal of Thoracic Oncology, 2012, 7, 1775-1780.	1.1	197
35	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology, 2017, 153, 1284-1294.e1.	1.3	189
36	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	1.1	182

#	Article	IF	CITATIONS
37	Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology guidelines. Diagnostic Cytopathology, 2014, 42, 338-350.	1.0	181
38	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i> -Positive Non–Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 2017, 1-13.	3.0	158
39	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discovery, 2019, 9, 1372-1387.	9.4	158
40	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discovery, 2018, 8, 600-615.	9.4	157
41	Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: Its Histopathologic Difference Between 2 Major Types. American Journal of Surgical Pathology, 2006, 30, 1561-1569.	3.7	154
42	PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer. Cancer Discovery, 2020, 10, 72-85.	9.4	154
43	A protein and mRNA expression-based classification of gastric cancer. Modern Pathology, 2016, 29, 772-784.	5.5	142
44	Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza. Chest, 2021, 159, 73-84.	0.8	142
45	Tumor Islands in Resected Early-stage Lung Adenocarcinomas are Associated With Unique Clinicopathologic and Molecular Characteristics and Worse Prognosis. American Journal of Surgical Pathology, 2013, 37, 287-294.	3.7	138
46	Cytology Adds Value to Imaging Studies for Risk Assessment of Malignancy in Pancreatic Mucinous Cysts. Annals of Surgery, 2011, 254, 977-983.	4.2	136
47	A multimodality test to guide the management of patients with a pancreatic cyst. Science Translational Medicine, 2019, 11, .	12.4	129
48	Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Science Translational Medicine, 2017, 9, .	12.4	128
49	Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nature Cell Biology, 2018, 20, 811-822.	10.3	124
50	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine, 2016, 3, 54-66.	6.1	123
51	EMR for Barrett's esophagus–related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointestinal Endoscopy, 2007, 66, 660-666.	1.0	120
52	Programmed Cell Death Ligand (PD-L1) Expression inÂStage II and III Lung Adenocarcinomas and NodalÂMetastases. Journal of Thoracic Oncology, 2017, 12, 458-466.	1.1	120
53	Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointestinal Endoscopy, 2016, 83, 140-148.	1.0	119
54	IPMN Involving the Main Pancreatic Duct. Annals of Surgery, 2015, 261, 976-983.	4.2	114

#	Article	IF	CITATIONS
55	Management of Superficial Barrett's Epithelium-Related Neoplasms by Endoscopic Mucosal Resection. American Journal of Surgical Pathology, 2005, 29, 680-686.	3.7	113
56	Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology Guidelines. CytoJournal, 2014, 11, 15.	1.7	112
57	Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	3.0	112
58	Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 341-344.	2.5	107
59	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell, 2021, 39, 1531-1547.e10.	16.8	106
60	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas. Annals of Surgery, 2018, 267, 157-163.	4.2	105
61	Patterns of Recurrence After Resection of IPMN. Annals of Surgery, 2015, 262, 1108-1114.	4.2	101
62	Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. Journal of Thoracic Oncology, 2015, 10, 951-959.	1.1	100
63	Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Modern Pathology, 2012, 25, 1462-1472.	5.5	98
64	Cytological criteria of highâ€grade epithelial atypia in the cyst fluid of pancreatic intraductal papillary mucinous neoplasms. Cancer Cytopathology, 2014, 122, 40-47.	2.4	94
65	<i>MET</i> Exon 14 Skipping in Non-Small Cell Lung Cancer. Oncologist, 2016, 21, 481-486.	3.7	94
66	Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration: The PIPE Study. Endoscopy, 2014, 46, 382-387.	1.8	90
67	Molecular Magnetic Resonance Imaging of Pulmonary Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 1120-1126.	2.9	89
68	Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 135-140.	1.1	88
69	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 872-877.	1.1	87
70	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. Cancer Biology and Medicine, 2016, 13, 157-170.	3.0	86
71	Buried Dysplasia and Early Adenocarcinoma Arising in Barrett Esophagus After Porfimer-photodynamic Therapy. American Journal of Surgical Pathology, 2007, 31, 403-409.	3.7	82
72	Global Genomic Analysis of Intraductal Papillary Mucinous Neoplasms of the Pancreas Reveals Significant Molecular Differences Compared to Ductal Adenocarcinoma. Annals of Surgery, 2009, 249, 440-447.	4.2	82

#	Article	IF	CITATIONS
73	Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. Journal of Thoracic Oncology, 2016, 11, 1869-1878.	1.1	81
74	PF4 Promotes Platelet Production and Lung Cancer Growth. Cell Reports, 2016, 17, 1764-1772.	6.4	80
75	Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. Developmental Cell, 2018, 44, 679-693.e5.	7.0	77
76	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 408-419.	2.5	70
77	Volumetric Optical Frequency Domain Imaging of Pulmonary Pathology With Precise Correlation to Histopathology. Chest, 2013, 143, 64-74.	0.8	69
78	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. Cancer Research, 2014, 74, 3146-3156.	0.9	69
79	Clinicopathologic Characteristics of BRG1-Deficient NSCLC. Journal of Thoracic Oncology, 2020, 15, 766-776.	1.1	68
80	Critical role for arginase 2 in obesity-associated pancreatic cancer. Nature Communications, 2017, 8, 242.	12.8	67
81	Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: Implications of minimal involvement of the main pancreatic duct. Surgery, 2014, 156, 611-621.	1.9	65
82	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Translational Lung Cancer Research, 2020, 9, 269-279.	2.8	64
83	Oncocytic-Type Intraductal Papillary Mucinous Neoplasms: A Unique Malignant Pancreatic Tumor with Good Long-Term Prognosis. Journal of the American College of Surgeons, 2015, 220, 839-844.	0.5	63
84	Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (â‰ 2 0-mm Invasive Component). Annals of Surgery, 2016, 263, 793-801.	4.2	60
85	Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN. Gastroenterology, 2021, 160, 1345-1358.e11.	1.3	60
86	Pancreatic duct glands (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair. Stem Cell Research, 2015, 15, 190-202.	0.7	59
87	mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN). Gut, 2014, 63, 1626.1-1634.	12.1	58
88	Update on large cell neuroendocrine carcinoma. Translational Lung Cancer Research, 2017, 6, 530-539.	2.8	58
89	Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms. Journal of Pathology, 2011, 224, 508-516.	4.5	56
90	The Prevalence and Clinicopathological Characteristics of High-Grade Pancreatic Intraepithelial Neoplasia. Pancreas, 2017, 46, 658-664.	1.1	56

#	Article	IF	CITATIONS
91	Molecular Pathology of Primary Non-small Cell Lung Cancer. Archives of Medical Research, 2020, 51, 784-798.	3.3	55
92	Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. Laboratory Investigation, 2020, 100, 4-15.	3.7	52
93	Invasive mucinous cystic neoplasms of the pancreas. Experimental and Molecular Pathology, 2012, 93, 345-349.	2.1	51
94	Grading epithelial atypia in endoscopic ultrasoundâ€guided fineâ€needle aspiration of intraductal papillary mucinous neoplasms: An international interobserver concordance study. Cancer Cytopathology, 2013, 121, 729-736.	2.4	51
95	Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS ONE, 2017, 12, e0182855.	2.5	51
96	Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. Annals of Surgery, 2019, 270, 1138-1146.	4.2	50
97	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440.		49
98	Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic <i>KLF4</i> mutations predominantly in low-grade regions. Gut, 2021, 70, 928-939.	12.1	48
99	Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Science Immunology, 2021, 6, .	11.9	47
100	Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation. Nature, 2019, 573, 139-143.	27.8	45
101	Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Clinical Cancer Research, 2016, 22, 4259-4270.	7.0	44
102	Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. Gastroenterology, 2019, 157, 720-730.e2.	1.3	44
103	Tumor spread through air spaces (STAS): prognostic significance of grading in non-small cell lung cancer. Modern Pathology, 2021, 34, 549-561.	5.5	44
104	PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocrine Pathology, 2018, 29, 59-67.	9.0	43
105	The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Modern Pathology, 2011, 24, 1177-1190.	5.5	42
106	A Role of Three-Dimensional (3D)-Reconstruction in the Classification of Lung Adenocarcinoma. Analytical Cellular Pathology, 2012, 35, 79-84.	1.4	42
107	Toward the Guidance of Transbronchial Biopsy. Chest, 2013, 144, 1261-1268.	0.8	42
108	Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. Surgery, 2015, 158, 1219-1225.	1.9	42

#	Article	IF	CITATIONS
109	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. Translational Lung Cancer Research, 2017, 6, 570-587.	2.8	42
110	Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice. Gastroenterology, 2016, 151, 1232-1244.e10.	1.3	40
111	Endobronchial Optical Coherence Tomography for Low-Risk Microscopic Assessment and Diagnosis of Idiopathic Pulmonary Fibrosis <i>In Vivo</i> . American Journal of Respiratory and Critical Care Medicine, 2018, 197, 949-952.	5.6	40
112	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2018, 268, 340-347.	4.2	39
113	Updates on spread through air spaces (STAS) in lung cancer. Histopathology, 2020, 77, 173-180.	2.9	39
114	Effect of Tumor Characteristics and Duplication of the Muscularis Mucosae on the Endoscopic Staging of Superficial Barrett Esophagus-related Neoplasia. American Journal of Surgical Pathology, 2009, 33, 620-625.	3.7	38
115	Immune checkpoint inhibitor-associated celiac disease. , 2020, 8, e000958.		38
116	Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology, 2017, 17, 920-926.	1.1	37
117	<i>Pten</i> -Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction. Cancer Discovery, 2013, 3, 908-921.	9.4	36
118	High-grade lung adenocarcinomas with micropapillary and/or solid patterns. Current Opinion in Pulmonary Medicine, 2014, 20, 317-323.	2.6	36
119	Cons: Can liquid biopsy replace tissue biopsy?—the US experience. Translational Lung Cancer Research, 2016, 5, 424-427.	2.8	36
120	Tumor islands and spread through air spaces: Distinct patterns of invasion in lung adenocarcinoma. Pathology International, 2016, 66, 1-7.	1.3	36
121	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology, 2020, 4, 21.	5.4	36
122	Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncology, The, 2022, 23, e62-e74.	10.7	36
123	Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 661-668.	3.3	35
124	Frequency and significance of calcification in IPMN. Pancreatology, 2013, 13, 43-47.	1.1	33
125	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods, 2015, 83, 118-127.	3.8	33
126	GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Modern Pathology, 2017, 30, 1720-1727.	5.5	33

#	Article	IF	CITATIONS
127	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal of Thoracic Oncology, 2018, 13, 205-217.	1.1	33
128	Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. Modern Pathology, 2019, 32, 511-523.	5.5	33
129	Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Modern Pathology, 2020, 33, 281-296.	5.5	33
130	Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 1308-1319.	4.1	33
131	REDD1 loss reprograms lipid metabolism to drive progression of <i>RAS</i> mutant tumors. Genes and Development, 2020, 34, 751-766.	5.9	30
132	Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Non–Small Cell Lung Cancer. Archives of Pathology and Laboratory Medicine, 2011, 135, 655-664.	2.5	30
133	Preoperative characteristics and cytological features of 136 histologically confirmed pancreatic mucinous cystic neoplasms. Cancer Cytopathology, 2017, 125, 169-177.	2.4	29
134	Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Scientific Reports, 2020, 10, 18278.	3.3	29
135	Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. International Journal of Nanomedicine, 2014, 9, 1891.	6.7	28
136	Characterization of epithelial subtypes of intraductal papillary mucinous neoplasm of the pancreas with endoscopic ultrasound and cyst fluid analysis. Endoscopy, 2014, 46, 1071-1077.	1.8	28
137	Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. Annals of Surgery, 2021, 274, e134-e142.	4.2	28
138	Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature Cancer, 2022, 3, 710-722.	13.2	28
139	Accurate Prediction of Nodal Status in Preoperative Patients with Pancreatic Ductal Adenocarcinoma Using Next-Gen Nanoparticle. Translational Oncology, 2013, 6, 670-675.	3.7	27
140	Texture Analysis of Magnetic Resonance Enterography Contrast Enhancement Can Detect Fibrosis in Crohn Disease Strictures. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 533-538.	1.8	26
141	Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	26
142	Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. Histopathology, 2019, 75, 649-659.	2.9	25
143	Significance of tumor spread through air spaces (STAS) in lung cancer from the pathologist perspective. Translational Lung Cancer Research, 2020, 9, 847-859.	2.8	25
144	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. Pathology, 2021, 53, 446-453.	0.6	25

#	Article	IF	CITATIONS
145	A Sizeâ€Selective Intracellular Delivery Platform. Small, 2016, 12, 5873-5881.	10.0	24
146	Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated With Cystic Airspaces: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2021, 216, 318-329.	2.2	24
147	Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 31-44.	2.8	23
148	Accuracy and Reproducibility of Intraoperative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas. Journal of Thoracic Oncology, 2021, 16, 619-629.	1.1	21
149	Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis. European Journal of Surgical Oncology, 2019, 45, 870-876.	1.0	20
150	Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	20
151	Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains. Scientific Reports, 2016, 6, 20390.	3.3	19
152	Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report. American Journal of Gastroenterology, 2018, 113, 632-633.	0.4	19
153	Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation. Journal of Thoracic Disease, 2019, 11, S37-S44.	1.4	19
154	Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 857-873.	5.6	19
155	AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth. Molecular Cancer Therapeutics, 2018, 17, 254-263.	4.1	18
156	Thoracic nuclear protein in testis (NUT) carcinoma: expanded pathological spectrum with expression of thyroid transcription factorâ€1 and neuroendocrine markers. Histopathology, 2021, 78, 896-904.	2.9	18
157	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	17
158	Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. Annals of the American Thoracic Society, 2020, 17, 550-554.	3.2	17
159	Assessment of the feasibility of frozen sections for the detection of spread through air spaces (STAS) in pulmonary adenocarcinoma. Modern Pathology, 2022, 35, 210-217.	5.5	17
160	Clinicopathological findings in patients with COVIDâ€19â€associated ischaemic enterocolitis. Histopathology, 2021, 79, 1004-1017.	2.9	17
161	Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergoing preoperative therapy. Cancer Science, 2018, 109, 871-878.	3.9	16
162	Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. Journal of Gastrointestinal Surgery, 2018, 22, 226-234.	1.7	16

#	Article	IF	CITATIONS
163	Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Modern Pathology, 2021, 34, 380-395.	5.5	16
164	Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, 8012-8012.	1.6	16
165	ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 147-155.	0.7	15
166	Determining malignancy in CT guided fine needle aspirate biopsy of subsolid lung nodules: Is core biopsy necessary?. European Journal of Radiology Open, 2019, 6, 175-181.	1.6	15
167	Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Scientific Reports, 2019, 9, 17145.	3.3	15
168	Evaluation of radiofrequency ablation using a 1â€Fr wire electrode in porcine pancreas, liver, gallbladder, spleen, kidney, stomach, and lymph nodes: A pilot study. Digestive Endoscopy, 2016, 28, 465-468.	2.3	14
169	Extranodal lymphomas of abdomen and pelvis: imaging findings and differential diagnosis. Abdominal Radiology, 2017, 42, 1096-1112.	2.1	14
170	Case 23-2020: A 76-Year-Old Woman Who Died from Covid-19. New England Journal of Medicine, 2020, 383, 380-387.	27.0	14
171	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. Archives of Pathology and Laboratory Medicine, 2020, 144, 1477-1489.	2.5	14
172	Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia–3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias. Human Pathology, 2010, 41, 902-909.	2.0	13
173	Evaluation of bipolar radiofrequency ablation for occluded self-expandable metal stents in the bile duct: in vivo and in vitro study. Endoscopy, 2015, 47, 1167-1170.	1.8	13
174	Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Scientific Reports, 2019, 9, 16832.	3.3	13
175	Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 3898-3912.	1.5	13
176	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	1.1	13
177	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology, 2021, 21, 1119-1126.	1.1	13
178	Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms. European Journal of Cardio-thoracic Surgery, 2019, 55, 691-698.	1.4	12
179	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. Clinical Cancer Research, 2021, 27, 2807-2815.	7.0	12
180	Napsin A/p40 antibody cocktail for subtyping nonâ€small cell lung carcinoma on cytology and small biopsy specimens. Cancer Cytopathology, 2016, 124, 472-484.	2.4	11

#	Article	IF	CITATIONS
181	Programmed deathâ€ligand 1 immunohistochemistry testing for nonâ€small cell lung cancer in practice. Cancer Cytopathology, 2017, 125, 521-528.	2.4	11
182	Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma. Biomarker Research, 2018, 6, 25.	6.8	11
183	Neoplastic–Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Molecular Cancer Research, 2020, 18, 1889-1902.	3.4	11
184	Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2022, 276, e518-e526.	4.2	11
185	E-Cigarette Use, Small Airway Fibrosis, and Constrictive Bronchiolitis. , 2022, 1, .		11
186	Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma. Human Pathology, 2016, 55, 151-158.	2.0	10
187	Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. , 2019, 7, 41.		10
188	Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2314-2325.	7.0	10
189	PD‣1 immunohistochemistry: Clones, cutoffs, and controversies. Apmis, 2022, 130, 295-313.	2.0	10
190	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. JCO Precision Oncology, 2022, , .	3.0	10
191	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, e155-e157.	1.1	9
192	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. Journal of Thoracic Oncology, 2019, 14, 835-843.	1.1	9
193	SWI/SNF protein and claudinâ€4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum. Histopathology, 2020, 77, 231-239.	2.9	9
194	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer–Transformed <i>EGFR</i> Mutant Non–Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 1, 1-7.	3.0	8
195	Expanded acceptance of acute exacerbation of nonspecific interstitial pneumonia, including 7 additional cases with detailed clinical pathologic correlation. Pathology International, 2018, 68, 401-408.	1.3	8
196	Loss of expression of MLH1 in nonâ€dysplastic crypts is a harbinger of neoplastic progression in sessile serrated adenomas/polyps. Histopathology, 2019, 75, 376-384.	2.9	8
197	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 6343-6353.	7.0	8
198	The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC Journal of Clinical Oncology, 2018, 36, 8544-8544.	1.6	8

#	Article	IF	CITATIONS
199	Imaging of pancreatic cystic lesions with confocal laser endomicroscopy: an ex vivo pilot study. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 5119-5126.	2.4	7
200	Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary Teams. Chest, 2018, 153, 876-887.	0.8	7
201	Digital Image Analysis for Estimating Stromal CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma. Journal of Pathology Informatics, 2021, 12, 28.	1.7	7
202	mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy. Human Pathology, 2021, 111, 36-44.	2.0	7
203	Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1472-1479.	2.5	7
204	Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. Modern Pathology, 2022, 35, 615-624.	5.5	7
205	PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis. International Journal of Pediatric Otorhinolaryngology, 2017, 95, 133-138.	1.0	6
206	High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. JCO Precision Oncology, 2017, 1, 1-9.	3.0	6
207	Case 28-2019: A 22-Year-Old Woman with Dyspnea and Chest Pain. New England Journal of Medicine, 2019, 381, 1059-1067.	27.0	6
208	Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics, 2020, 12, 996.	4.5	6
209	Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy Journal of Clinical Oncology, 2014, 32, 8053-8053.	1.6	6
210	Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression Journal of Clinical Oncology, 2018, 36, 9011-9011.	1.6	6
211	Barrett esophagus: Diagnostic challenges. Seminars in Diagnostic Pathology, 2014, 31, 100-113.	1.5	5
212	Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 669-677.	1.2	5
213	Rebuttal from Dr. Mino-Kenudson. Translational Lung Cancer Research, 2016, 5, 430-432.	2.8	4
214	Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. Annals of Thoracic Surgery, 2017, 103, e123-e125.	1.3	4
215	Cytological reporting on lung <scp>FNA</scp> and small biopsy specimens in the era of personalized medicine. Cancer Cytopathology, 2017, 125, 155-160.	2.4	4
216	Microscopic size measurements in postâ€neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Histopathology, 2020, 77, 144-155.	2.9	4

#	Article	IF	CITATIONS
217	Contrast-enhanced computed tomography prior to percutaneous transthoracic needle biopsy reduces the incidence of hemorrhage. Annals of Translational Medicine, 2021, 9, 288-288.	1.7	4
218	Cytology adds value to monoclonal antibody Das-1 testing for detection of high-risk pancreatic cysts. Journal of the American Society of Cytopathology, 2021, 10, 249-254.	0.5	4
219	Clinicopathological characteristics of squamous cell carcinoma of the lung with programmed cell death ligand 1 (PD-L1) protein expression Journal of Clinical Oncology, 2015, 33, 7554-7554.	1.6	4
220	Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC) Journal of Clinical Oncology, 2018, 36, 8571-8571.	1.6	4
221	Analysis of VEGF/PIGF heterodimer level in pancreatic cyst fluid as a biomarker for serous cystadenoma. Journal of the American Society of Cytopathology, 2015, 4, 79-83.	0.5	3
222	Immunohistochemistry in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS. Archives of Pathology and Laboratory Medicine, 2018, 142, 792-793.	2.5	3
223	A Case of Adult Pancreatoblastoma With Novel APC Mutation and Genetic Heterogeneity. Frontiers in Oncology, 2021, 11, 725290.	2.8	3
224	Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Pancreatology, 2021, 21, 1506-1515.	1.1	3
225	Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs) Journal of Clinical Oncology, 2014, 32, 8031-8031.	1.6	3
226	Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression Journal of Clinical Oncology, 2015, 33, 7555-7555.	1.6	3
227	Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs. Biomaterials, 2022, 285, 121509.	11.4	3
228	Will spread through air spaces be a staging parameter in lung cancer?. Journal of Thoracic Disease, 2018, 10, 593-596.	1.4	2
229	Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC—Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?. Journal of Thoracic Oncology, 2021, 16, 1247-1249.	1.1	2
230	Clinicopathologic features of non-small cell lung cancer (NSCLC) harboring an <i>NTRK</i> gene fusion Journal of Clinical Oncology, 2017, 35, 11580-11580.	1.6	2
231	ARDS With Pneumothorax in a Young Adult. Chest, 2022, 161, e111-e116.	0.8	2
232	Reply to: Endobronchial Optical Coherence Tomography: Shining New Light on Diagnosing UIP?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	2
233	Abstract 5172: B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma. Cancer Research, 2022, 82, 5172-5172.	0.9	2
234	Reply to Wijmans et al.: Optical Coherence Tomography: A Valuable Novel Tool for Assessing the Alveolar Compartment in Interstitial Lung Disease?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1232-1233.	5.6	1

#	Article	IF	CITATIONS
235	Is the Programmed Death-Ligand 1 73-10 Immunohistochemistry Assay Compatible With the 22C3 Assay?. Journal of Thoracic Oncology, 2020, 15, 1265-1267.	1.1	1
236	The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma Journal of Clinical Oncology, 2021, 39, 9538-9538.	1.6	1
237	Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura. Annals of Thoracic Surgery, 2020, 112, 1862-1869.	1.3	1
238	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC) Journal of Clinical Oncology, 2018, 36, 8573-8573.	1.6	1
239	A retrospective analysis of the prevalence of <i>EGFR</i> or <i>KRAS</i> mutations in patients (pts) with crizotinib-naÃīve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2013, 31, 8083-8083.	1.6	1
240	Differential expression of immune inhibitory markers in association with HLA class I and the immune microenvironment in resected lung adenocarcinomas Journal of Clinical Oncology, 2017, 35, 8551-8551.	1.6	1
241	Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis Journal of Clinical Oncology, 2022, 40, 2507-2507.	1.6	1
242	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes Journal of Clinical Oncology, 2021, 39, e16253-e16253.	1.6	0
243	Abstract 94: Multi-compartment reprogramming and spatially-resolved interactions in frozen pancreatic cancer with and without neoadjuvant chemotherapy and radiotherapy at single-cell resolution. , 2021, , .		Ο
244	3Dâ€based approach for efficient analysis of immunostained histology images in evaluating downstream pathway activation in malignant tumors with molecular targets. FASEB Journal, 2013, 27, 52.5.	0.5	0
245	The role of molecular profiling to differentiate multiple lung primary adenocarcinomas from intrapulmonary metastases from a lung primary Journal of Clinical Oncology, 2013, 31, 7555-7555.	1.6	Ο
246	Biologic heterogeneity of <i>KRAS</i> -mutated lung adenocarcinomas (K-ADC) Journal of Clinical Oncology, 2016, 34, 8532-8532.	1.6	0
247	Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2018, 36, 12083-12083.	1.6	0
248	Single-nucleus RNA-seq of frozen archival primary pancreatic ductal adenocarcinoma uncovers multi-compartment intratumoral heterogeneity associated with neoadjuvant treatment Journal of Clinical Oncology, 2020, 38, 4633-4633.	1.6	0
249	Reply to the Letter to the Editor From Zhou etÂal. Journal of Thoracic Oncology, 2020, 15, e136-e137.	1.1	0
250	Abstract PO-097: Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. , 2021, , .		0
251	Spatially defined enrichment of a neuronal-like malignant phenotype in pancreatic cancer after neoadjuvant treatment Journal of Clinical Oncology, 2022, 40, 610-610.	1.6	0
252	Clinicopathologic characteristics and outcomes for patients with <i>KRAS</i> G12D-mutant non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2022, 40, e21024-e21024.	1.6	0

#	Article	IF	CITATIONS
253	Abstract SY12-04: Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy. Cancer Research, 2022, 82, SY12-04-SY12-04.	0.9	Ο